Johns Hopkins ABX Guide
Entecavir
INDICATIONS
FDA
FDA
- Treatment of chronic hepatitis B (HBV) infection in adults and children at ≥2 years of age with evidence of active disease (active viral replication, persistent elevations in serum aminotransferases, or histologic evidence of active disease).
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: September 6, 2026
Citation
Soto, Caitlin, and Janessa Smith. "Entecavir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2026. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540200/all/Entecavir.
Soto C, Smith J. Entecavir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540200/all/Entecavir. Accessed September 15, 2026.
Soto, C., & Smith, J. (2026). Entecavir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540200/all/Entecavir
Soto C, Smith J. Entecavir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. [cited 2026 September 15]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540200/all/Entecavir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Entecavir
ID - 540200
A1 - Soto,Caitlin,PharmD, BCIDP
AU - Smith,Janessa,Pharm.D. BCPS
Y1 - 2026/09/06/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540200/all/Entecavir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
